Professor and Chair, Radiation Oncology; and Professor, Urology, UCSF
Investigator, Comprehensive Minority Institution/Cancer Center Partnership, San Francisco State University and UCSF Helen Diller Family Comprehensive Cancer Center
| CONTACT | |
|
(415) 353-9807 (appts) Box 1708, UCSF; San Francisco, CA 94143-1708 |
additional websites: |
| EDUCATION | |
|
Morehouse College, Atlanta, GA, BS, 1975, Physics
|
|
| PROFESSIONAL EXPERIENCE | |
|
1987-1988 |
Acting Chief, Radiation Oncology Service, VA Medical Center, Martinez, CA |
|
1988-1990 |
Chief, Radiation Oncology Service, VA Medical Center, Martinez, CA |
|
1990-1994 |
Assistant Professor, Department of Radiation Oncology, UCSF |
|
1994-2000 |
Associate Professor, Department of Radiation Oncology, UCSF |
|
2000-present |
Professor, Department of Radiation Oncology & Urology, UCSF |
|
2001-present |
Director, Clinical Research, Department of Radiation Oncology, UCSF |
|
2003-present |
Vice Chair, Department of Radiation Oncology, UCSF |
|
2006-present |
Interim Chair, Department of Radiation Oncology |
| HONORS & AWARDS | |
|
(partial listing) |
|
|
1980-1981 |
Outstanding Intern of the Year (Charles R. Drew Award) |
|
1981-1982 |
Fellow of the American Cancer Society |
|
1994 |
UCSF Health Net Wellness Award |
|
1994-1997 |
American Cancer Society Careeer Development Award |
|
1996-97; 1997-98; 2001-02 |
"The Best Doctors in America" |
|
2002 |
Fellow, American College of Radiology |
|
2002-05 |
President, John Hale Medical Society |
|
2005 |
10 Most Influential African Americans in the Bay Area (Healthcare) |
| SELECTED PUBLICATIONS | |
|
Pouliot, J., Aubin, M., Langen, K.M., Liu, Y-M., Pickett, B., Shinohara, K., Roach, M. (Non)-Migration of Radio-opague Markers used for on-line Localization of the Prostate EPID. Int J Radiat Oncol Biol Phys 56(3): 862-866, 2003. | |
|
Langen, K.M., Pouliot, J., Anezinos, C., Aubin, M., Gottschalk, A.R., Hsu, I-C., Lowther, D., Liu, Y-M., Shinohara, K., Verhey, L., Weinberg, V., Roach III, M. Evaluation of ultrasound-based prostate localization for image guided radiation therapy. Int J Radiat Oncol Biol Phys 57: 634-44, 2003. | |
|
Michalski, J.M., Winter, K., Purdy, J.A., Wilder, R.B., Perez, C.A., Roach, M., et al. Preliminary evaluation of low grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys 56(1):192-198, 2003. | |
|
Roach, M., 3rd, Lu, J., Pilepich M.V., Asbell, S.O., Mohiuddin, M., Grignon, D. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials. J Urol 169 (1):245-250, 2003. | |
|
Roach, M., Weinberg, V., McLaughlin, P.W., Grossfeld, G. et al. Serum Prostate Specific Antigen (PSA) and Survival Following External Beam Radiotherapy for Carcinoma of the Prostate. Urology 61(4): 730-735, 2003. | |
|
Roach, M., DeSilvio, M., Lawton, C., Uhl, V., Machtay, M., Seider, M.J. et al.. A Phase III Trial Comparing Whole Pelvic versus Prostate Only Radiotherapy and Neoadjuvant versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group (RTOG) 9413. J Clin Oncol 21 (10):1904 -11, 2003. | |
|
Takamiya, R., Weinberg, V., Young, C.D., McLaughlin, P., Sandler, H., Roach, M. A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2003; 56:1073-1078. | |
|
DeWitt, K., Roach, M., Weinberg, V., McLaughlin, P., Sandler, H. What does postradiotherapy PSA nadir tell us about freedom from PSA failure and progression-free survival in patients with low and intermediate-risk localized prostate cancer? Urology 2003; 62:492-496. | |
|
Roach M, 3rd. Hormonal therapy and radiotherapy for localized prostate cancer: who, where and how long? J Urol 2003;170:S35-40; discussion S40-31. | |
|
Chakravarti A, Heydon K, Wu CL, Pollack A, Roach M et al. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10. J Clin Oncol 2003; 21: 3328-3334. | |
|
Scher HI, Eisenberger M, D'Amico AV, Halabi, S, Small, E. J., Morris, M., Kattan, M. W., Roach, M., et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004; 22:537-556. | |
|
Michalski JM, Winter K, Purdy JA Perez, C. A., Ryu, J. K., Parliament, M. B., Valicenti, R. K., Roach, M. et al. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Int J Radiat Oncol Biol Phys 2004;58: 735-742. | |
|
Gottschalk AR, Roach M, 3rd. The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials. Br J Cancer 2004; 90:950-954. | |
|
Coakley, F. V., Teh, H. S., Qayyum, A., Swanson, M. G., Lu, Y., Roach, M., 3rd, Pickett, B., Shinohara, K., Vigneron, D. B., Kurhanewicz, J. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 233 (2): 441-8, 2004. | |
|
Pickett, B., Haken, R.K, Kurhanewicz, J., Shinohara, K., Vigneron, D., Fein, B., Roach III, M. Time Course to Metabolic Atrophy Following Permanent Prostate Seed Implantation Based on Magnetic Resonance Spectroscopic Imaging. Int J Radiat Oncol Biol Phys 59:665-73, 2004. | |
|
Millender LE, Aubin M, Pouliot J, Shinohara K, Roach M. Daily Electronic Portal Imaging for Morbidly obese Men Undergoing Radiotherapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 59:6-10, 2004. | |
|
Zelefsky, M. J., Moughan, J., Owen, J., Zietman, A. L., Roach, M., 3rd. Hanks, G. E., Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 patterns of care survey for prostate cancer. Int J Radiat Oncol Biol Phys 59:1053-61, 2004. | |
|
Roach, M., 3rd. Reducing the toxicity associated with the use of radiotherapy in men with localized prostate cancer. Urol Clin North Am 31: 353-66, 2004. | |
|
Pollack, A., DeSilvio, M., Khor, L. Y., Li, R., Al-Saleem, T. I., Hammond, M. E., Venkatesan, V., Lawton, C. A., Roach, M., 3rd,et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol 22:2133-40, 2004. | |
|
Li, R., Heydon, K., Hammond, M. E., Grignon, D. J., Roach, M., 3rd et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res 10: 4118-24, 2004. | |
|
Roach M, Winter K, Michalski JM, et al. Penile Bulb Dose and Impotence Following 3D Conformal Radiotherapy For Prostate Cancer on RTOG 9406: Findings from a Prospective Multi-institutional Phase I-II Dose Escalation Study. Int J Radiat Oncol Biol Phys 60 (5): 1351-6, 2004. | |
|
Liu, Y-M., Ling, S., Langen, K.M., Shinohara, K., Weinberg, V., Roach, M. Prostate Movement during Simulation Resulting from Retrograde Urethrogram Compared with ÒNaturalÓ Prostate Movement. . Int J Radiat Oncol Biol Phys 60:470-5, 2004. | |
|
Pickett B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach M. Use of Magnetic Resonance Imaging and Spectroscopy (MRSI) in the Evaluation of External Beam Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 60:1047-1055, 2004. | |
|
Pouliot J, Bani-Hashemi A, Chen J, Svatos M, Ghelmansarai F, Mitschke M, Aubin M, Xia P, Morin O, Bucci K, Roach M, Hernandez P, Zheng Z, Hristov D, Verhey L. Low-Dose Megavoltage Cone-Beam CT For Radiation Therapy. Int J Radiat Oncol Biol Phys (61(2): 238-246, 2005. | |
|
Michalski JM, Winter K, Purdy JA, Parliament M, Wong H, Perez CA, Roach M, Bosch W, Cox J. Toxicity After Three-Dimensional Radiotherapy for Prostate Cancer on RTOG 9406 Dose Level V. Int J Radiation Oncology Biol Phys 62(3):706-713, 2005. | |
|
Morris DE, Emami B, Mauch PM, Konski, A. A., Tao, M. L., Ng, A. K., Klein, E. A., Mohideen, N., Hurwitz, M. D., Fraas, B. A., Roach, M., 3rd, Gore, E. M., Tepper, J. E.et al. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys. 62(1):3-19, 2005. | |
|
Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. Jun 1 2005; 97 (11):798-80, 2005. | |
|
Bucci MK, Bevan A, Roach M, 3rd. Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin 55(2):117-134, 2005 | |
|
Speight, J.L., and Roach, M., Radiotherapy in the Management of Clinically Localized Prostate Cancer: Evolving Standards, Consensus, Controversies and New Directions. J Clin Oncol 23:8176-85, 2005. | |
|
Shipley WU, Desilvio M, Pilepich MV, Roach, M., 3rd, et al. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10. Int J Radiat Oncol Biol Phys 64:1162-7, 2006. | |
|
Pickett B, Kurhanewicz J, Pouliot J, Weinberg, V., Shinohara, K., Coakley, F., Roach, M., 3rd, et al. Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level. Int J Radiat Oncol Biol Phys 2006. | |
|
Abdel-Wahab M, Berkey BA, Krishan, A, O'Brien, T., Hammond, E., Roach, M., et al. Influence of number of CAG repeats on local control in the RTOG 86-10 protocol. Am J Clin Oncol 2006;29: 14-20. |
|
|
1/8/07 |
|


